

ACQUISITION OPPORTUNITY – GUAYAMA, PUERTO RICO

WORLD CLASS SOLID DOSAGE MANUFACTURING OPERATION




Pfizer Inc has made the strategic decision to consolidate its manufacturing operations and is offering its Guayama, Puerto Rico pharmaceutical manufacturing site for acquisition. This site is comprised of 830,000 square feet of building space and is focused on the manufacture of oral solid dosage products including tablets and capsules. PharmaBioSource, Inc. is working with Pfizer to market the Puerto Rico-based sites that are being divested.

The Opportunity:

The site is located in Guayama, Puerto Rico, 55 miles (88 kilometers) from San Juan on the south east coast of the Island. The state-of-the-art manufacturing facility currently produces a range of products serving diverse global markets and represents a cost-effective alternative to new construction. Acquisition of the Guayama solid dosage manufacturing site would provide:

- Access to a high capacity, state-of-the-art solid dosage manufacturing facility, including high containment (OEB 4 and 5), spheroids manufacturing, active overcoating and diverse packaging capabilities.
- Facilities may be acquired intact or divided into several separate facilities.
- Access to a skilled Life Sciences work force.
- Excellent site infrastructure with opportunities for expansion.
- Facilities with an excellent regulatory approval record and ease of access to global markets including the US, Latin America, Europe and Asian markets.
- The opportunity to take advantage of the favorable corporation tax regime in Puerto Rico to reduce taxes payable on global profits derived from pharmaceutical products manufactured on the Island.
- Up to 50% tax credit on qualified R&D expenses.



Highlights of the facilities include:

- Significant solid oral dosage form capacity, including high containment facilities suited for the manufacture of cytotoxic or potent compounds (OEB 4 / 5) and DEA controlled substances:
 - Total solid dosage capacity is over 20 billion tablets and 2 billion capsules per annum.
 - Specialized manufacturing capacity, including spheroids manufacturing and active overcoating.
 - Highly integrated automation of the manufacturing modules, including SCADA, Data Historian, automated inspection and the use of process analytical technologies
- Extensive bottle and blister packaging capabilities:
 - Five high speed bottling lines with annual capacity of over 140 million bottles.
 - Six blister lines with annual capacity of over 100 million packs.
- Laboratory and development facilities:
 - Modern, well equipped QC laboratories as well as process development and technology transfer facilities including highly contained bench-scale test production facilities.
- Extensive utility infrastructure, new warehouse facilities and administrative support facilities.



Interested parties should contact PharmaBioSource, Inc., the exclusive marketing firm for this opportunity, for more information regarding an acquisition of this World-Class Solid Dosage manufacturing facility from Pfizer. Additional information is also available on its web site:

www.pharmabiosource.com/pfizerdivestments

FOR FURTHER INFORMATION, PLEASE CONTACT:

CHARLIE SHAFRAN

Project Leader

Cell: 917.821.7693

cshafran@pharmabiosource.com

OLGA MORALES VENTURA

Technical Information

Cell: 484.459.4943

oventura@pharmabiosource.com

BILL WIEDERSEIM

Technical Information

Cell: 610.888.9806

wiederseim@pharmabiosource.com

No representation or warranty, express or implied, is given by Pfizer, PharmaBioSource Inc or their respective advisers or any of their respective directors or employees or any other person as to the accuracy or completeness of the contents of this summary information. The only representations and warranties that will be made are those that may eventually be included in a definitive agreement for the proposed transaction, if any. Neither this summary nor any of the information contained in it shall form the basis of purchase or acquire any shares or assets in the facility or any interest in it.

